Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins
The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as we...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/9/915 |
id |
doaj-f1a2cfa501954d43a45a1a7456942625 |
---|---|
record_format |
Article |
spelling |
doaj-f1a2cfa501954d43a45a1a74569426252020-11-25T03:01:39ZengMDPI AGViruses1999-49152020-08-011291591510.3390/v12090915Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating ImmunoglobulinsTill Koch0Monika Rottstegge1Paula Ruibal2Sergio Gomez-Medina3Emily V. Nelson4Beatriz Escudero-Pérez5Matthias Pillny6My Linh Ly7Fara Raymond Koundouno8Joseph Akoi Bore9N’Faly Magassouba10Christine Dahlke11Stephan Günther12Miles W. Carroll13Marylyn M. Addo14César Muñoz-Fontela15Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyClinical Psychology and Psychotherapy, Institute of Psychology, Faculty of Psychology and Human Movement Science, University of Hamburg, 20146 Hamburg, GermanyDivision of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyMinistry of Health Guinea, 2101 Conakry, GuineaMinistry of Health Guinea, 2101 Conakry, GuineaUniversité Gamal Abdel Nasser de Conakry, 2101 Conakry, GuineaDivision of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyResearch and Development Institute, National Infection Service, Public Health England, Porton Down, Salisbury, Wilts SP40JG, UKDivision of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyBernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, GermanyThe last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.https://www.mdpi.com/1999-4915/12/9/915Ebola virusVSVvaccineantibodiesimmune memory. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Till Koch Monika Rottstegge Paula Ruibal Sergio Gomez-Medina Emily V. Nelson Beatriz Escudero-Pérez Matthias Pillny My Linh Ly Fara Raymond Koundouno Joseph Akoi Bore N’Faly Magassouba Christine Dahlke Stephan Günther Miles W. Carroll Marylyn M. Addo César Muñoz-Fontela |
spellingShingle |
Till Koch Monika Rottstegge Paula Ruibal Sergio Gomez-Medina Emily V. Nelson Beatriz Escudero-Pérez Matthias Pillny My Linh Ly Fara Raymond Koundouno Joseph Akoi Bore N’Faly Magassouba Christine Dahlke Stephan Günther Miles W. Carroll Marylyn M. Addo César Muñoz-Fontela Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins Viruses Ebola virus VSV vaccine antibodies immune memory. |
author_facet |
Till Koch Monika Rottstegge Paula Ruibal Sergio Gomez-Medina Emily V. Nelson Beatriz Escudero-Pérez Matthias Pillny My Linh Ly Fara Raymond Koundouno Joseph Akoi Bore N’Faly Magassouba Christine Dahlke Stephan Günther Miles W. Carroll Marylyn M. Addo César Muñoz-Fontela |
author_sort |
Till Koch |
title |
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins |
title_short |
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins |
title_full |
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins |
title_fullStr |
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins |
title_full_unstemmed |
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccines Despite Similar Levels of Circulating Immunoglobulins |
title_sort |
ebola virus disease survivors show more efficient antibody immunity than vaccines despite similar levels of circulating immunoglobulins |
publisher |
MDPI AG |
series |
Viruses |
issn |
1999-4915 |
publishDate |
2020-08-01 |
description |
The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates. |
topic |
Ebola virus VSV vaccine antibodies immune memory. |
url |
https://www.mdpi.com/1999-4915/12/9/915 |
work_keys_str_mv |
AT tillkoch ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT monikarottstegge ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT paularuibal ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT sergiogomezmedina ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT emilyvnelson ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT beatrizescuderoperez ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT matthiaspillny ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT mylinhly ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT fararaymondkoundouno ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT josephakoibore ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT nfalymagassouba ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT christinedahlke ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT stephangunther ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT mileswcarroll ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT marylynmaddo ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins AT cesarmunozfontela ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccinesdespitesimilarlevelsofcirculatingimmunoglobulins |
_version_ |
1724692723713179648 |